These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 16143522

  • 1. Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists.
    Ahmed M, Briggs MA, Bromidge SM, Buck T, Campbell L, Deeks NJ, Garner A, Gordon L, Hamprecht DW, Holland V, Johnson CN, Medhurst AD, Mitchell DJ, Moss SF, Powles J, Seal JT, Stean TO, Stemp G, Thompson M, Trail B, Upton N, Winborn K, Witty DR.
    Bioorg Med Chem Lett; 2005 Nov 01; 15(21):4867-71. PubMed ID: 16143522
    [Abstract] [Full Text] [Related]

  • 2. Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists.
    Trani G, Baddeley SM, Briggs MA, Chuang TT, Deeks NJ, Johnson CN, Khazragi AA, Mead TL, Medhurst AD, Milner PH, Quinn LP, Ray AM, Rivers DA, Stean TO, Stemp G, Trail BK, Witty DR.
    Bioorg Med Chem Lett; 2008 Oct 15; 18(20):5698-700. PubMed ID: 18793848
    [Abstract] [Full Text] [Related]

  • 3. Bicyclic piperazinylbenzenesulphonamides are potent and selective 5-HT6 receptor antagonists.
    Bromidge SM, Clarke SE, King FD, Lovell PJ, Newman H, Riley G, Routledge C, Serafinowska HT, Smith DR, Thomas DR.
    Bioorg Med Chem Lett; 2002 May 20; 12(10):1357-60. PubMed ID: 11992776
    [Abstract] [Full Text] [Related]

  • 4. 5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists.
    Liu KG, Robichaud AJ, Bernotas RC, Yan Y, Lo JR, Zhang MY, Hughes ZA, Huselton C, Zhang GM, Zhang JY, Kowal DM, Smith DL, Schechter LE, Comery TA.
    J Med Chem; 2010 Nov 11; 53(21):7639-46. PubMed ID: 20932009
    [Abstract] [Full Text] [Related]

  • 5. Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134).
    Bromidge SM, Clarke SE, Gager T, Griffith K, Jeffrey P, Jennings AJ, Joiner GF, King FD, Lovell PJ, Moss SF, Newman H, Riley G, Rogers D, Routledge C, Serafinowska H, Smith DR.
    Bioorg Med Chem Lett; 2001 Jan 08; 11(1):55-8. PubMed ID: 11140733
    [Abstract] [Full Text] [Related]

  • 6. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist.
    Riemer C, Borroni E, Levet-Trafit B, Martin JR, Poli S, Porter RH, Bös M.
    J Med Chem; 2003 Mar 27; 46(7):1273-6. PubMed ID: 12646038
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.
    Schaus JM, Thompson DC, Bloomquist WE, Susemichel AD, Calligaro DO, Cohen ML.
    J Med Chem; 1998 May 21; 41(11):1943-55. PubMed ID: 9599243
    [Abstract] [Full Text] [Related]

  • 8. 8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
    Heightman TD, Gaster LM, Pardoe SL, Pilleux JP, Hadley MS, Middlemiss DN, Price GW, Roberts C, Scott CM, Watson JM, Gordon LJ, Holland VA, Powles J, Riley GJ, Stean TO, Trail BK, Upton N, Austin NE, Ayrton AD, Coleman T, Cutler L.
    Bioorg Med Chem Lett; 2005 Oct 01; 15(19):4370-4. PubMed ID: 16039851
    [Abstract] [Full Text] [Related]

  • 9. 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives as 5-HT6 receptor antagonists.
    Zhao SH, Berger J, Clark RD, Sethofer SG, Krauss NE, Brothers JM, Martin RS, Misner DL, Schwab D, Alexandrova L.
    Bioorg Med Chem Lett; 2007 Jun 15; 17(12):3504-7. PubMed ID: 17485206
    [Abstract] [Full Text] [Related]

  • 10. 6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.
    Bromidge SM, Duckworth M, Forbes IT, Ham P, King FD, Thewlis KM, Blaney FE, Naylor CB, Blackburn TP, Kennett GA, Wood MD, Clarke SE.
    J Med Chem; 1997 Oct 24; 40(22):3494-6. PubMed ID: 9357513
    [No Abstract] [Full Text] [Related]

  • 11. Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists.
    Cole DC, Lennox WJ, Stock JR, Ellingboe JW, Mazandarani H, Smith DL, Zhang G, Tawa GJ, Schechter LE.
    Bioorg Med Chem Lett; 2005 Nov 01; 15(21):4780-5. PubMed ID: 16125933
    [Abstract] [Full Text] [Related]

  • 12. Structure-activity relationship studies of CNS agents. Part 14: Structural requirements for the 5-HT1A and 5-HT2A receptor selectivity of simple 1-(2-pyrimidinyl)piperazine derivatives.
    Mokrosz JL, Strekowski L, Duszyńska B, Harden DB, Mokrosz MJ, Bojarski AJ.
    Pharmazie; 1994 Nov 01; 49(11):801-6. PubMed ID: 7838864
    [Abstract] [Full Text] [Related]

  • 13. Modification of the structure of 4, 6-disubstituted 2-(4-alkyl-1-piperazinyl)pyridines: synthesis and their 5-HT2A receptor activity.
    Paluchowska MH, Bojarski AJ, Bugno R, Charakchieva-Minol S, Wesołowska A.
    Arch Pharm (Weinheim); 2003 Apr 01; 336(2):104-10. PubMed ID: 12761763
    [Abstract] [Full Text] [Related]

  • 14. Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT₆ receptor antagonists.
    Nirogi R, Shinde A, Daulatabad A, Kambhampati R, Gudla P, Shaik M, Gampa M, Balasubramaniam S, Gangadasari P, Reballi V, Badange R, Bojja K, Subramanian R, Bhyrapuneni G, Muddana N, Jayarajan P.
    J Med Chem; 2012 Nov 08; 55(21):9255-69. PubMed ID: 23006002
    [Abstract] [Full Text] [Related]

  • 15. Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release.
    Marcos B, Gil-Bea FJ, Hirst WD, García-Alloza M, Ramírez MJ.
    Eur J Neurosci; 2006 Sep 08; 24(5):1299-306. PubMed ID: 16987217
    [Abstract] [Full Text] [Related]

  • 16. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.
    Borthwick AD, Davies DE, Exall AM, Livermore DG, Sollis SL, Nerozzi F, Allen MJ, Perren M, Shabbir SS, Woollard PM, Wyatt PG.
    J Med Chem; 2005 Nov 03; 48(22):6956-69. PubMed ID: 16250654
    [Abstract] [Full Text] [Related]

  • 17. Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task.
    Perez-García G, Meneses A.
    Pharmacol Biochem Behav; 2005 Jul 03; 81(3):673-82. PubMed ID: 15964617
    [Abstract] [Full Text] [Related]

  • 18. Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB-258585 after intrahippocampal administration to rats.
    Wesołowska A, Nikiforuk A, Stachowicz K.
    Behav Pharmacol; 2007 Sep 03; 18(5-6):439-46. PubMed ID: 17762512
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia.
    Xiong Y, Ullman B, Choi JS, Cherrier M, Strah-Pleynet S, Decaire M, Dosa PI, Feichtinger K, Teegarden BR, Frazer JM, Yoon WH, Shan Y, Whelan K, Hauser EK, Grottick AJ, Semple G, Al-Shamma H.
    J Med Chem; 2010 Aug 12; 53(15):5696-706. PubMed ID: 20684606
    [Abstract] [Full Text] [Related]

  • 20. 5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.
    Haydar SN, Yun H, Andrae PM, Mattes J, Zhang J, Kramer A, Smith DL, Huselton C, Graf R, Aschmies S, Schechter LE, Comery TA, Robichaud AJ.
    J Med Chem; 2010 Mar 25; 53(6):2521-7. PubMed ID: 20170099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.